Why the stock rally fizzled — plus, our latest thinking on Goldman and Bristol Myers
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
You are not logged in so some information on this page has been withheld. To see more, please log in.
Bristol Myers
since
auto-detected in 31 stories
6 days ago
41 days ago
Why we're lowering our Bristol Myers price target despite an earnings beat, guidance raise
Shares of Bristol Myers Squibb fell modestly after the drugmaker's better-than-expected first-quarter results.
81 days ago
JPMorgan says own this drug stock. It's one Jim Cramer is itching to buy again
The Club remains optimistic about Bristol Myers and shares JPMorgan's enthusiasm about Cobenfy.
page 1 of 1